142 related articles for article (PubMed ID: 7955904)
1. Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo.
Hawkins PN
Clin Sci (Lond); 1994 Sep; 87(3):289-95. PubMed ID: 7955904
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and monitoring of amyloidosis.
Hawkins PN
Baillieres Clin Rheumatol; 1994 Aug; 8(3):635-59. PubMed ID: 7954867
[TBL] [Abstract][Full Text] [Related]
3. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.
Jager PL; Hazenberg BP; Franssen EJ; Limburg PC; van Rijswijk MH; Piers DA
J Nucl Med; 1998 Apr; 39(4):699-706. PubMed ID: 9544684
[TBL] [Abstract][Full Text] [Related]
4. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression.
Hawkins PN; Richardson S; MacSweeney JE; King AD; Vigushin DM; Lavender JP; Pepys MB
Q J Med; 1993 Jun; 86(6):365-74. PubMed ID: 8171184
[TBL] [Abstract][Full Text] [Related]
5. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.
Gillmore JD; Lovat LB; Persey MR; Pepys MB; Hawkins PN
Lancet; 2001 Jul; 358(9275):24-9. PubMed ID: 11454373
[TBL] [Abstract][Full Text] [Related]
6. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis.
Hawkins PN
Curr Opin Nephrol Hypertens; 2002 Nov; 11(6):649-55. PubMed ID: 12394612
[TBL] [Abstract][Full Text] [Related]
7. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis.
Hawkins PN; Aprile C; Capri G; Viganò L; Munzone E; Gianni L; Pepys MB; Merlini G
Eur J Nucl Med; 1998 Jul; 25(7):701-8. PubMed ID: 9662591
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis.
Hazenberg BP; van Rijswijk MH; Piers DA; Lub-de Hooge MN; Vellenga E; Haagsma EB; Hawkins PN; Jager PL
Am J Med; 2006 Apr; 119(4):355.e15-24. PubMed ID: 16564782
[TBL] [Abstract][Full Text] [Related]
9. A primed state exists in vivo following histological regression of amyloidosis.
Hawkins PN; Pepys MB
Clin Exp Immunol; 1990 Aug; 81(2):325-8. PubMed ID: 2387095
[TBL] [Abstract][Full Text] [Related]
10. Micro-imaging of amyloid in mice.
Wall JS; Paulus MJ; Gleason S; Gregor J; Solomon A; Kennel SJ
Methods Enzymol; 2006; 412():161-82. PubMed ID: 17046658
[TBL] [Abstract][Full Text] [Related]
11. Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component.
Hawkins PN; Myers MJ; Epenetos AA; Caspi D; Pepys MB
J Exp Med; 1988 Mar; 167(3):903-13. PubMed ID: 3351437
[TBL] [Abstract][Full Text] [Related]
12. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis.
Hawkins PN; Richardson S; Vigushin DM; David J; Kelsey CR; Gray RE; Hall MA; Woo P; Lavender JP; Pepys MB
Arthritis Rheum; 1993 Jun; 36(6):842-51. PubMed ID: 8507227
[TBL] [Abstract][Full Text] [Related]
13. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients.
Lovat LB; Persey MR; Madhoo S; Pepys MB; Hawkins PN
Gut; 1998 May; 42(5):727-34. PubMed ID: 9659172
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.
Hawkins PN; Lavender JP; Pepys MB
N Engl J Med; 1990 Aug; 323(8):508-13. PubMed ID: 2377176
[TBL] [Abstract][Full Text] [Related]
15. Imaging of experimental amyloidosis with 131I-labeled serum amyloid P component.
Caspi D; Zalzman S; Baratz M; Teitelbaum Z; Yaron M; Pras M; Baltz ML; Pepys MB
Arthritis Rheum; 1987 Nov; 30(11):1303-6. PubMed ID: 3689465
[TBL] [Abstract][Full Text] [Related]
16. Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component.
Nelson SR; Hawkins PN; Richardson S; Lavender JP; Sethi D; Gower PE; Pugh CW; Winearls CG; Oliver DO; Pepys MB
Lancet; 1991 Aug; 338(8763):335-9. PubMed ID: 1677697
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component.
Hawkins PN; Myers MJ; Lavender JP; Pepys MB
Lancet; 1988 Jun; 1(8600):1413-8. PubMed ID: 2898580
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis.
Hazenberg BP; van Rijswijk MH; Lub-de Hooge MN; Vellenga E; Haagsma EB; Posthumus MD; Jager PL
J Nucl Med; 2007 Jun; 48(6):865-72. PubMed ID: 17504868
[TBL] [Abstract][Full Text] [Related]
19. Amyloidosis: a review of recent diagnostic and therapeutic developments.
Gillmore JD; Hawkins PN; Pepys MB
Br J Haematol; 1997 Nov; 99(2):245-56. PubMed ID: 9375734
[TBL] [Abstract][Full Text] [Related]
20. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis.
Hawkins PN; Wootton R; Pepys MB
J Clin Invest; 1990 Dec; 86(6):1862-9. PubMed ID: 2254450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
